CN1921889A - 靶定的免疫原 - Google Patents

靶定的免疫原 Download PDF

Info

Publication number
CN1921889A
CN1921889A CNA2004800421537A CN200480042153A CN1921889A CN 1921889 A CN1921889 A CN 1921889A CN A2004800421537 A CNA2004800421537 A CN A2004800421537A CN 200480042153 A CN200480042153 A CN 200480042153A CN 1921889 A CN1921889 A CN 1921889A
Authority
CN
China
Prior art keywords
sequence
amino acid
seq
polypeptide
hper1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800421537A
Other languages
English (en)
Chinese (zh)
Inventor
A·R·昂格尔
D·萨尔哈
S·加利钱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SANOFI PASTEUR Inc
Original Assignee
SANOFI PASTEUR Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SANOFI PASTEUR Inc filed Critical SANOFI PASTEUR Inc
Publication of CN1921889A publication Critical patent/CN1921889A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNA2004800421537A 2003-12-31 2004-12-30 靶定的免疫原 Pending CN1921889A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53372803P 2003-12-31 2003-12-31
US60/533,728 2003-12-31

Publications (1)

Publication Number Publication Date
CN1921889A true CN1921889A (zh) 2007-02-28

Family

ID=34748948

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800421537A Pending CN1921889A (zh) 2003-12-31 2004-12-30 靶定的免疫原

Country Status (12)

Country Link
US (1) US20060002946A1 (enExample)
EP (1) EP1699492A2 (enExample)
JP (1) JP2007536911A (enExample)
KR (1) KR20060129353A (enExample)
CN (1) CN1921889A (enExample)
AU (1) AU2004312548A1 (enExample)
BR (1) BRPI0418273A (enExample)
CA (1) CA2552251A1 (enExample)
IL (1) IL176603A0 (enExample)
MX (1) MXPA06007574A (enExample)
WO (1) WO2005066203A2 (enExample)
ZA (1) ZA200605304B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0103110D0 (en) * 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
WO2012123755A1 (en) 2011-03-17 2012-09-20 The University Of Birmingham Re-directed immunotherapy
KR20170116039A (ko) * 2015-02-18 2017-10-18 에프. 호프만-라 로슈 아게 표적 세포에 대항하여 t 세포 세포독성을 특이적으로 유도하기 위한 면역컨주게이트
CA2984629C (en) 2015-05-07 2024-06-18 University Of South Florida Modified ube3a gene for a gene therapy approach for angelman syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE391791T1 (de) * 2000-08-25 2008-04-15 Aventis Pharma Inc Membran penetrierende peptide und deren anwendungen
CA2477429A1 (en) * 2002-01-29 2003-08-07 Robert A. Uger Targeted immunogens

Also Published As

Publication number Publication date
WO2005066203A2 (en) 2005-07-21
IL176603A0 (en) 2006-10-31
US20060002946A1 (en) 2006-01-05
WO2005066203A3 (en) 2005-09-01
JP2007536911A (ja) 2007-12-20
BRPI0418273A (pt) 2007-05-02
EP1699492A2 (en) 2006-09-13
MXPA06007574A (es) 2007-04-17
KR20060129353A (ko) 2006-12-15
AU2004312548A1 (en) 2005-07-21
CA2552251A1 (en) 2005-07-21
ZA200605304B (en) 2007-12-27

Similar Documents

Publication Publication Date Title
CN1184320C (zh) Mhc－ⅱ类配体作为疫苗佐剂以及lag－3用于癌症治疗的应用
CN1805758A (zh) 核酸和细胞疫苗的组分
HK1040261A1 (zh) 负调节osteoprotegerin配体活性的方法
CN1705739A (zh) 用作抗原递送系统的抗原转导的t细胞
CN1910198A (zh) 用于预防和/或治疗癌症的肿瘤抗原
US8530442B2 (en) Modified CEA nucleic acid and expression vectors
CN1871025A (zh) 基于印记位点调节物兄弟(boris)的预防性癌症疫苗
CN1658899A (zh) 经修饰的cea核酸及表达载体
US8911991B2 (en) Multi-antigen vectors of melanoma
CN1802174A (zh) 用于预防和/或治疗癌症的肿瘤抗原bfa5
US20040002455A1 (en) Targeted immunogens
US20030148973A1 (en) MAGE-A1 peptides for treating or preventing cancer
US20060002946A1 (en) Targeted immunogens
CN1334873A (zh) 新型肿瘤抗原蛋白art－1及其肿瘤抗原肽
HK1102553A (en) Targeted immunogens
KR101162970B1 (ko) 변형된 ｃｅａ/ｂ7 벡터
AU2003216119A1 (en) Targeted immunogens
CN1878566B (zh) 用于黑素瘤的多抗原载体
HK1045173A1 (zh) 多肽
CA2481719C (en) Modified cea nucleic acid and expression vectors
HK1081227A (en) Antigen transduced t cells used as a delivery system for antigens
HK1093899A (en) Nucleotide and cellular vaccine composition
HK1030014B (en) Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1102553

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1102553

Country of ref document: HK